- Home
- IRON vs DGNX Comparison
IRON vs DGNX Comparison
Compare IRON & DGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- DGNX
- Stock Information
- Founded
- IRON 2017
- DGNX 2018
- Country
- IRON United States
- DGNX United Kingdom
- Employees
- IRON N/A
- DGNX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- DGNX
- Sector
- IRON Health Care
- DGNX
- Exchange
- IRON Nasdaq
- DGNX NYSE
- Market Cap
- IRON 1.4B
- DGNX 1.2B
- IPO Year
- IRON N/A
- DGNX 2025
- Fundamental
- Price
- IRON $46.68
- DGNX $53.81
- Analyst Decision
- IRON Strong Buy
- DGNX
- Analyst Count
- IRON 9
- DGNX 0
- Target Price
- IRON $93.89
- DGNX N/A
- AVG Volume (30 Days)
- IRON 354.8K
- DGNX 49.3K
- Earning Date
- IRON 05-07-2025
- DGNX 01-01-0001
- Dividend Yield
- IRON N/A
- DGNX N/A
- EPS Growth
- IRON N/A
- DGNX N/A
- EPS
- IRON N/A
- DGNX N/A
- Revenue
- IRON N/A
- DGNX $1,177,066.00
- Revenue This Year
- IRON N/A
- DGNX N/A
- Revenue Next Year
- IRON N/A
- DGNX N/A
- P/E Ratio
- IRON N/A
- DGNX N/A
- Revenue Growth
- IRON N/A
- DGNX N/A
- 52 Week Low
- IRON $30.82
- DGNX $3.60
- 52 Week High
- IRON $68.73
- DGNX $155.00
- Technical
- Relative Strength Index (RSI)
- IRON 49.90
- DGNX N/A
- Support Level
- IRON $44.85
- DGNX N/A
- Resistance Level
- IRON $47.36
- DGNX N/A
- Average True Range (ATR)
- IRON 2.23
- DGNX 0.00
- MACD
- IRON -0.12
- DGNX 0.00
- Stochastic Oscillator
- IRON 37.58
- DGNX 0.00
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.